Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury

Summary

The primary objective of this trial is to assess the impact of CRMD-001 on markers of contrast-induced acute kidney injury (AKI) in high-risk patients with chronic kidney disease (CKD) undergoing coronary angiography and PCI.

Timeline

Start

2010-06

Primary completion

2011-06

Completion

2011-06

Drugs

Indications